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TO THE EDITOR
UVB irradiation of the skin induces a
complex cascade of acute inflamma-
tion, characterized by erythema, ede-
ma, and immunosuppression and is
according to chronic exposure subse-
quently linked to the initiation and
progression of skin cancer (Matsumura
and Ananthaswamy, 2004). The role of
inflammatory mediators in skin diseases
is of critical importance. This includesAbbreviations: F2-IsoPs, F2-isoprostanes; DCLF, diclofenac; COX, cyclo-oxygenase
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the release of cytokines, NO, and
oxidized arachidonic acid derivatives
(Reilly et al., 2000; Rhodes et al.,
2001). The so-called eicosanoid lipid
mediators are formed by two main
pathways: enzymatically and non-
enzymatically. Inflammatory stimuli in-
duce the liberation of arachidonic acid
from membrane phospholipids and the
formation of prostaglandins, which are
generated by cyclo-oxygenase (COX)
isoenzymes and are blocked by non-
steroidal anti-inflammatory drugs. Pros-
taglandins are known as bioactive
products with vasoregulatory properties
acting in a synergistic or antagonistic
manner. Whereas PGE2 mediates vaso-
dilatation, PGF2a is responsible for
vasoconstriction. The non-enzymatical
pathway of arachidonic acid oxidation
includes free radical mechanisms and
synthesis of F2-isoprostanes (F2-IsoPs),
which are mostly bound to the back-
bone of phospholipids (Morrow et al.,
1992). F2-IsoPs are a novel group of
prostaglandin-like compounds with
potent biological activities, as evi-
denced by their pulmonary and renal
vasoconstrictive effects (Lawson et al.,
1999). Several studies have indicated
associations between isoprostanes and
severe inflammatory conditions (Basu,
2004). Although F2-IsoPs are preferen-
tially formed non-enzymatically, a
COX-dependent generation can not be
excluded (Klein et al., 1996; Lawson
et al., 1999). Therefore, F2-IsoPs are not
only biomarkers of lipid peroxidation
and potential in vivo indicators of
oxidant stress in various clinical condi-
tions, but also mediators of acute
inflammation (Basu, 2004; Montuschi
et al., 2004).
Diclofenac (DCLF) belongs to the
most common non-steroidal anti-inflam-
matory drugs used for the treatment of
pain and inflammation. DCLF (2-[(2,6-
dichlorophenyl)amino] phenyl-acetate)
non-selectively inhibits COX-1 and
COX-2, which both catalyze prostaglan-
din synthesis (Hickey et al., 2001).
It was the aim of our study to test the
hypotheses that
1. low-dose UVB irradiation influ-
ences the concentrations of F2-
IsoPs and prostaglandins in vitro
in human HaCaT keratinocytes and
in vivo in the interstitial fluid of the
dermis and this could be a dose-
dependent action.
2. application of non-toxic concentra-
tions of DCLF can lower the levels of
enzymatically and of non-enzymati-
cally formed lipid mediators as well.
3. HaCaT keratinocytes may serve as
a suitable in vitro model to reflect
UVB- and DCLF-induced altera-
tions of lipid mediators in vivo.
HaCaT Keratinocytes
In this study, we showed early evidence
that in HaCaT keratinocytes both F2-
IsoPs and PGF2a can reliably be quanti-
fied by gas chromatography–mass spec-
trometry (negative ion chemical ioniza-
tion–selected ion monitoring (Table 1a)
and that their concentrations were
dose-dependently enhanced with low-
dose UVB irradiation between 30 and
100 mJ/cm2 (Figure 1). 8-iso-PGF2a as
marker of non-enzymatic arachidonic
acid oxidation exclusively reflects
phospholipid-bound F2-IsoPs, because
(i) it occurred in HaCaT keratinocytes
completely in the esterified and not in
the free form (experiments according to
Wiswedel et al., 2004) and (ii) no 8-iso-
PGF2a was released and detected in
the cell-free supernatant (Quist et al.,
2006). Concerning 9a,11a-PGF2a, it can
be assumed that the main part repre-
sents COX-catalyzed generation. This
was derived from the predominant
occurrence in the free and non-ester-
ified form (about 77%) and by the
considerable release of PGF2a in the
supernatant (Quist et al., 2006). COX-
derived PGE2 was not detectable in
HaCaT cells, but was completely re-
leased in the supernatant (Table 1a).
The UVB-induced enhancement of
PGE2 was definitely more pronounced
compared with the other mediators.
In Figure 1, it is shown that 8-iso-
PGF2a concentrations were slightly and
more continuously increased up to
100 mJ/cm2, whereas 9a,11a-PGF2a
concentrations already reached a max-
imum at 50 mJ/cm2 with a more than
fivefold enhancement compared with
the non-irradiated control values and
dropped down thereafter to about half-
maximum levels. The decrease of PGF2a
in HaCaTs may reflect the enhanced
release in the supernatant as shown by
Quist et al. (2006) or a partial transfor-
mation to the more stable 15-keto-
dihydro-PGF2a, which was not ana-
lyzed in this study. The different UVB
dependence of 8-iso-PGF2a and 9a,11a-
PGF2a may be an additional indication
Table 1a. Levels of F2-isoprostanes/prostaglandins in HaCaT keratinocytes
and supernatants – Influence of UVB irradiation and DCLF
8-iso-PGF2a 9a,11a-PGF2a PGE2
(pmol/mg protein
in HaCaTs)
(pmol/mg protein
in HaCaTs)
(pmol/ml
supernatant)
Non-irradiated cells 0.2370.03 0.5070.06 0.2170.08
(n=26) (n=22) (n=3)
UVB (30 mJ/cm2) 0.3570.06 1.2170.28 62.5718.8
(n=19) (n=17) (n=3)
UVB (30 mJ/cm2) 0.3270.07 0.9570.03* n.d.
+2.5 mM DCLF (n=6) (n=6)
UVB (30 mJ/cm2) 0.2370.05* 0.7970.18* 0.2570.05
+5.0 mM DCLF (n=6) (n=6) (n=3)
DCLF, diclofenac; n.d., not determined.
Values are means7SEM for HaCaT cells and7SD for supernatants. Values of non-irradiated and
UVB-irradiated HaCaT keratinocytes (30 mJ/cm2) are identical with those of Figure 1.
*For 8-iso-PGF2a, UVB+5 mM DCLF is significantly different from UVB (Po0.05). In the case of 9a,
11a-PGF2a, UVB+2.5 mM DCLF as well as UVB+5 mM DCLF are significantly different vs UVB (P=0.010
and 0.004); Student’s t-test.
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for their different origin: free radical-
catalyzed or COX-derived. The results
correspond to those of Pentland et al.
(1990) showing fivefold increases of
PGF2a and PGE2 in human skin explants
following 120 mJ/cm2 UVB irradiation
and those of Buckman et al. (1998),
demonstrating Western blots with six-
fold increases of COX-2 protein in
cultured human keratinocytes 24 hours
following 30 mJ/cm2 UVB exposure. In
a next set of experiments, the influence
of DCLF on the UVB-induced enhance-
ment of prostanoids was investigated
(Table 1a). The DCLF concentrations
used in HaCaT keratinocytes were be-
tween 1 and 5mM and a low, but
effective, UVB dose of 30 mJ/cm2 was
chosen. Concentrations of 1mM DCLF or
less were not effective at all and con-
centrations of 10mM and higher were
proven to be toxic to HaCaT cell cultures.
The UVB-induced increases of 8-iso-
PGF2a and of 9a,11a-PGF2a were sup-
pressed by about 35 % with 5mM DCLF,
whereas only that of 9a,11a–PGF2a were
suppressed by about 12 % with 2.5mM
DCLF (Table 1a). PGE2 concentrations
were followed in the supernatant. In
contrast to the mediators before, they
were about 300-fold enhanced by UVB
and nearly totally reduced to control
levels by DCLF (Table 1a).
Microdialysis
The results obtained with HaCaT kera-
tinocytes in vitro have been qualitatively
confirmed using a microdialysis techni-
que, which has been used in human
studies for more than 10 years (Stahl
et al., 2002; Grundmann et al., 2004).
Six healthy female volunteers, 18–30
years old, were included in the study
after giving their written, informed con-
sent and after approval by the ethics
committee of the Medical Faculty,
Otto-von-Guericke-University Magde-
burg, Germany. The Declarations of
Helsinki Principles were followed.
Microdialysis allows the ‘‘near in
vivo’’ measurement of endogeneous
eicosanoid mediators released in the
interstitial space of the dermis under
control and inflammatory conditions
(Table 1b). Whereas UVB- and DCLF-
induced alterations of 9a,11a-PGF2a
concentrations were not significant,
the concentrations of 8-iso-PGF2a and
PGE2 were four and 2.7-fold enhanced
24 hours following UVB treatment in
comparison with healthy untreated
skin. DCLF, topically applied as cream
or gel, immediately after UVB irradia-
tion, prevented the generation of an
erythema and reduced the levels of 8-
iso-PGF2a and PGE2 remarkably (Table
1b). The anti-inflammatory effect of
DCLF was more pronounced for the
5% cream than for the 1% gel. As found
in HaCaT cells, DCLF did not only
influence the prostaglandin, but addi-
tionally the isoprostane pathway. The
so-called radical scavenging or antiox-
idant side effects of DCLF were also
described by Aruoma and Halliwell
(1988) and Maffei Facino et al. (1993).
Prostanoid concentrations measured
by gas chromatography–mass spectro-
metry in this study were on the same
level as isoprostane concentrations
reported by Karamouzis et al. (2004)
in dialysate samples from muscle and
PGE2 levels in microdialysates of hu-
man skin reported by Fairweather et al.
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Figure 1. Dose-dependent enhancement of F2-isoprostane/prostaglandin concentrations in human
HaCaT keratinocytes following UVB irradiation. Endogenous concentrations of isoprostanes/
prostaglandins under control conditions (corresponding to 100 %) and following 30 mJ/cm2 are presented
in Table 1a. UVB irradiation was performed as described in Supplementary Text. 50 mJ/cm2:
0.5570.07 pmol 8-iso-PGF2a /mg protein and 2.5970.42 pmol 9a,11a-PGF2a/mg protein; n¼6.
100 mJ/cm2: 0.7370.40 pmol 8-iso-PGF2a /mg protein and 1.3570.45 pmol 9a,11a-PGF2a /mg protein;
n¼ 6. Values are means7SEM. Significance between different doses (each versus the corresponding
lower dose) was calculated by Student’s t-test: *Po0.05, **Po0.01. In the case of 8-iso-PGF2a , the
difference between 100 and 50 mJ/cm2 was not significant (P¼ 0.069), but the difference between 100
and 30 mJ/cm2 was significant (P¼0.026).
Table 1b. Levels of F2-isoprostanes/prostaglandins in microdialysis samples
of human skin – influence of UVB irradiation and treatment with DCLF
8-iso-PGF2a 9a,11a- PGF2a PGE2
(pmol/ml micro-
dialysate)
(pmol/ml micro-
dialysate)
(pmol/ml micro-
dialysate)
Non-irradiated skin 0.2570.11 0.5370.25 0.6270.14
UVB 1.0070.22* 0.3870.28 1.6570.23*
UVB+DCLF (1%) 0.5970.09** 0.6270.35 0.9770.13**
UVB+DCLF (5%) 0.4170.12** 0.5570.30 0.8170.12**
DCLF, diclofenac.
Values are means7SEM of n=6 healthy volunteers.
UVB irradiation (about 20–40 mJ/cm2) caused the formation of erythema of stages 3–5, which were
completely suppressed by DCLF immediately applicated following UVB irradiation. Samples were
taken 24 h later; after an additional hour of ‘‘baseline’’ microdialysis for equilibration. Microdialysate
samples of about 2 hours have to be combined for triplicate analyses. Differences in the levels of
prostanoids are significant for 8-iso-PGF2a and PGE2 according to Student’s t-test.
*Po0.05 vs non-irradiated control and **Po0.05 vs UVB without DCLF.
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(2004). UVB-induced increases of 8-
iso-PGF2a were also shown by Schnei-
der et al. (2006) in human skin biopsies
and by Kuhn et al. (2006) in suction
blister fluid 24 hours post-irradiation.
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